News for Immunocore Holdings plc (IMCR)

Revenue: Fourth quarter net sales of $84.1 million, slightly below the estimated revenue of $85.73 million.Annual Revenue: Total net sales for 2024 reached $31

KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle m

Immunocore Holdings PLC (IMCR) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue is $85.73 million, and the ear

**media[544278]**

**media[511556]**

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

Immunocore Holdings PLC (IMCR), a leading biotechnology company, has outlined its strategic priorities for 2025, focusing on expanding its melanoma franchise an

Summary Immunocore Holdings PLC (IMCR), a commercial-stage biotechnology company known for its pioneering work in immunomodulating medicines, announced its part

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025)

**media[504080]**

Summary Immunocore Holdings PLC (IMCR), a commercial-stage biotechnology company known for its innovative immunomodulating medicines, announced the appointment

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

Summary Immunocore Holdings PLC (IMCR), a leading biotechnology company, announced on December 23, 2024, the commencement of a Phase 1 clinical trial for its no

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRA

The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by 2033.

Baker Brothers' 13F portfolio value decreased from $7.97B to $7.83B this quarter. Click here to read more about its fund holdings.

Baker Brothers' 13F portfolio value declines but continues to hold significant stakes in biopharmaceutical companies and boasts past successful. Read more here.

Loading... Loading... Shares of Science Applications International Corporation SAIC declined 11% to $119.91 following first-quarter results. SAIC reported a 9...

ArriVent BioPharma adds Kristine Peterson to its Board